Ikarian Capital’s Moderna MRNA Stock Holding History

Ikarian Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-100,000	Closed	-$13.1M	–	256
2021 Q1	$13.1M	Buy	+100,000	New	+$14.5M	0.44%	50
2020 Q3	–	Sell	-30,000	Closed	-$1.93M	–	199
2020 Q2	$1.93M	Buy	+30,000	New	+$1.64M	0.15%	108

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ikarian Capital's MRNA Position: Q1 2024 in Review

Ikarian Capital sold out of Moderna (MRNA) in Q1 2024, closing a stake of 24,546 shares — an estimated $2.44M sold.

Ikarian Capital first reported a position in MRNA in Q4 2020 and held it in 2 quarters. The position peaked at $6.48M in Q4 2020. 902 funds tracked by Wall St. Rank hold MRNA as of Q1 2024.

Ikarian Capital reported no remaining Moderna position as of Q1 2024 after selling out during the quarter.
Ikarian Capital sold 24,546 Moderna shares in Q1 2024, an estimated $2.44M.
Ikarian Capital first reported a position in Moderna in Q4 2020 and held it in 2 quarters.
Ikarian Capital's Moderna position peaked at $6.48M in Q4 2020.
902 funds tracked by Wall St. Rank held Moderna as of Q1 2024.

Based on Ikarian Capital's 13F filing for Q1 2024, filed 15 May 2024.